Diploma (LON:DPLM - Get Free Report)'s stock had its "hold" rating restated by investment analysts at Shore Capital in a research report issued on Thursday, Marketbeat.com reports. They presently have a GBX 5,100 ($68.46) price target on the stock. Shore Capital's price target suggests a potential downside of 1.92% from the company's current price.
Diploma Trading Down 0.4%
Shares of LON:DPLM traded down GBX 20 ($0.27) during mid-day trading on Thursday, reaching GBX 5,200 ($69.80). 190,932 shares of the company's stock were exchanged, compared to its average volume of 398,739. The firm has a market capitalization of £6.94 billion, a price-to-earnings ratio of 59.77, a PEG ratio of 2.82 and a beta of 0.75. The business's fifty day moving average price is GBX 4,712.35 and its 200-day moving average price is GBX 4,363.24. The company has a debt-to-equity ratio of 62.17, a quick ratio of 0.80 and a current ratio of 2.17. Diploma has a twelve month low of GBX 3,532 ($47.41) and a twelve month high of GBX 5,625 ($75.50).
Diploma (LON:DPLM - Get Free Report) last issued its quarterly earnings results on Wednesday, May 21st. The company reported GBX 80.20 ($1.08) EPS for the quarter. Diploma had a net margin of 9.25% and a return on equity of 13.18%. On average, research analysts predict that Diploma will post 163.7995512 EPS for the current fiscal year.
Insiders Place Their Bets
In related news, insider Katie Bickerstaffe bought 44 shares of the company's stock in a transaction on Wednesday, May 21st. The shares were purchased at an average cost of GBX 4,867 ($65.33) per share, for a total transaction of £2,141.48 ($2,874.47). Insiders have bought 96 shares of company stock worth $473,173 in the last 90 days. 0.52% of the stock is currently owned by insiders.
About Diploma
(
Get Free Report)
Diploma PLC, together with its subsidiaries, supplies specialized technical products and services in the United Kingdom, Continental Europe, North America, and internationally. It operates through three business sectors: Life Sciences, Seals, and Controls. The Life Sciences sector supplies technology-enabled products used in surgical procedures in operating theatres and endoscopy; testing equipment and services for clinical laboratories; and bio-pharma, food safety and testing, and other research-oriented products.
Further Reading
Before you consider Diploma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Diploma wasn't on the list.
While Diploma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
